Assenagon Asset Management S.A. purchased a new stake in shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 5,706 shares of the biotechnology company’s stock, valued at approximately $362,000.
Other large investors have also recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the third quarter valued at approximately $275,000. Mason Street Advisors LLC lifted its position in Arrowhead Pharmaceuticals by 2.2% during the third quarter. Mason Street Advisors LLC now owns 32,360 shares of the biotechnology company’s stock valued at $912,000 after purchasing an additional 711 shares during the period. Envestnet Asset Management Inc. lifted its position in Arrowhead Pharmaceuticals by 5.5% during the third quarter. Envestnet Asset Management Inc. now owns 33,800 shares of the biotechnology company’s stock valued at $952,000 after purchasing an additional 1,753 shares during the period. Parametric Portfolio Associates LLC lifted its position in Arrowhead Pharmaceuticals by 60.1% during the second quarter. Parametric Portfolio Associates LLC now owns 80,302 shares of the biotechnology company’s stock valued at $2,128,000 after purchasing an additional 30,147 shares during the period. Finally, Dupont Capital Management Corp bought a new position in Arrowhead Pharmaceuticals during the third quarter valued at approximately $620,000. Hedge funds and other institutional investors own 70.33% of the company’s stock.
ARWR opened at $44.61 on Friday. Arrowhead Pharmaceuticals Inc has a 1-year low of $12.72 and a 1-year high of $73.72. The company has a market capitalization of $4.27 billion, a PE ratio of 64.65 and a beta of 1.97. The firm’s 50 day simple moving average is $61.53 and its two-hundred day simple moving average is $42.34.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Monday, November 25th. The biotechnology company reported $0.11 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.14 by ($0.03). Arrowhead Pharmaceuticals had a return on equity of 32.30% and a net margin of 40.27%. The business had revenue of $43.29 million during the quarter, compared to the consensus estimate of $36.97 million. As a group, research analysts expect that Arrowhead Pharmaceuticals Inc will post -0.16 earnings per share for the current year.
In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 100,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $67.50, for a total value of $6,750,000.00. Following the transaction, the chief executive officer now directly owns 2,048,684 shares in the company, valued at $138,286,170. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kenneth Allen Myszkowski sold 40,313 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $49.44, for a total transaction of $1,993,074.72. Following the completion of the transaction, the chief financial officer now owns 424,536 shares in the company, valued at $20,989,059.84. The disclosure for this sale can be found here. Insiders sold 286,402 shares of company stock worth $17,138,919 over the last quarter. Insiders own 4.80% of the company’s stock.
A number of research analysts recently weighed in on the stock. Cantor Fitzgerald restated a “neutral” rating and set a $50.00 price objective (up previously from $24.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, November 19th. Piper Jaffray Companies increased their price objective on shares of Arrowhead Pharmaceuticals from $72.00 to $80.00 and gave the company an “overweight” rating in a research report on Monday, December 9th. Leerink Swann assumed coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. They set an “underperform” rating and a $32.00 price objective on the stock. Oppenheimer assumed coverage on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. They set a “hold” rating on the stock. Finally, S&P Equity Research restated a “buy” rating on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, November 26th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $61.14.
Arrowhead Pharmaceuticals Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company’s pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Recommended Story: Most Active Stocks
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.